Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Investors

Breadcrumb

  1. Home
  2. Investors
  3. Corporate Social Responsibility

Sustainability and Corporate Social Responsibility

Annual Reports on Corporate Social Responsibility Policy

 

Date Title
February 2020 Annual Report on Corporate Social Responsibility Policy 2019 (Spanish only)
February 2019 Annual Report on Corporate Social Responsibility Policy 2018 (Spanish only)
February 2018 Annual Report on Corporate Social Responsibility Policy 2017 (Spanish only)
February 2017 Annual Report on Corporate Social Responsibility Policy 2016 (Spanish only)
February 2016 Annual Report on Corporate Social Responsibility Policy 2015 (Spanish only)

 

Corporate Social Responsibility Principles
Corporate Social Responsibility Principles
Compliance Policy

Since it was founded in 2000, Oryzon Genomics S.A. has grown in a responsible, prudent manner, with an efficient management of its resources and with a clear commitment to research and development. We work to develop new epigenetics-based therapeutics with the aim to improve human health, focusing on therapeutic areas with unmet medical needs.

We strive to develop our activities committed to the highest standards of business ethics and with the unalterable willingness to comply with all applicable legislation.

The Board of Directors and the management team of Oryzon Genomics S.A. are firmly committed to continuing to develop and raise awareness among the employees on matters related to the compliance with the law and with the company values.

As part of the company’s compliance program, Oryzon’s Board of Directors approved on 29th July 2019 the Compliance Model and the Code of Ethics and Conduct that shall be binding to everyone working at Oryzon Genomics S.A.

Letter of presentation of the Compliance Model (Spanish) Compliance Policy (Spanish)

 

 

Policy regarding communication and contacts with shareholders, institutional investors and proxy advisors

The policy regarding communication and contacts with shareholders, institutional investors and proxy advisors, approved by the Board of Directors, aims to generate confidence in the Company’s national and foreign shareholders and investors and to promote transparency in the information that the Company makes public.

Policy regarding communication and contacts with shareholders, institutional investors and proxy advisors (Spanish)

 

 

Code of Ethics and Conduct

The purpose of Oryzon’s Code of Ethics and Conduct, approved by the Board of Directors on 29th July 2006, is to formalize the Company’s commitment to the principles of business ethics and transparency in all our areas of action, establishing a set of principles and guidelines aimed at guaranteeing the ethical and responsible behavior of all of the persons concerned in the performance of their duties.

Code of Ethics and Conduct
Whistleblower Channel

The Whistleblower Channel is available to all employees and other people related to the company, such as directors, shareholders, suppliers and business partners of Oryzon,  who have or may have knowledge of the commission of any irregularity of potential significance, including financial and accounting irregularities, or any act contrary to the law or to the rules set out in our Code of Ethics and Conduct.  Anonymous reports in good faith, including all necessary data, will also be accepted.

The Whistleblower Channel guarantees:

  • The confidentiality of the identity of the Whistleblower
  • The absence of any form of retaliation, discrimination and penalty against employees who report alleged breaches in good faith
  • The respect for the rights of the persons allegedly involved in a possible breach
  • The exhaustive analysis of the information on the basis of which the Whistleblower files the report

Reports may be filed:

  • By filling in the electronic form available below

SEND REPORT 

  • By sending the following reporting form to the email canaldedenuncias@oryzon.com

Whistleblowing reporting form

Personal Data Protection

The personal data provided by the interested party will be kept under the ownership of ORYZON GENOMICS, S.A. and processed in accordance with the provisions of the Personal Data Protection section of the Whistleblower Channel Policy.

 

Whistleblower Policy

  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy